Scholar Rock announces press release on apitegromab CHMP opinion timing for SMA MAA

SCHOLAR ROCK HOLDING CORP

SCHOLAR ROCK HOLDING CORP

SRRK

0.00
  • Scholar Rock flagged a delay risk for an EMA CHMP opinion on apitegromab’s MAA in spinal muscular atrophy.
  • Timing hinges on the FDA’s inspection classification for Catalent Indiana’s fill-finish site following an April 2026 inspection.
  • If reclassified, the CHMP opinion is expected later in 2026; otherwise the MAA may shift to a second fill-finish facility.
  • U.S. BLA review continues with a Sept. 30, 2026 PDUFA action date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scholar Rock Holding Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202607200800BIZWIRE_USPR_____20260719_BW465114) on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.